Guest analyst, Kim Logan, drops in to share her reflections on generic giant Mylan NV's second quarter performance and shares her thoughts on the company maintaining investment grade ratings.
09/06/17 • 11 min
Generate a badge
Get a badge for your website that links back to this episode
Select type & size
<a href="https://goodpods.com/podcasts/s-and-p-pharma-dose-101886/episode-22-reflections-mylan-nv-earnings-2q17-5355208"> <img src="https://storage.googleapis.com/goodpods-images-bucket/badges/generic-badge-1.svg" alt="listen to episode 22: reflections - mylan nv earnings 2q17 on goodpods" style="width: 225px" /> </a>
Copy